2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME
C. Dean Buckner, MD

ASCO 2007: Update on the Management of Genitourinary Malignancies
Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center

Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer (3/12/2010)
Researchers affiliated with the RTOG 94-08 clinical trial have reported that short-term androgen deprivation therapy (ADT) delivered before and during moderate-dose radiation therapy improves survival and reduces risk of recurrence compared with radiation alone in men with intermediate-risk, early-stage prostate cancer. The results of this Phase III study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco on March 5-7.

Updated Survival Data on Provenge® for Treatment of Hormone Refractory Prostate Cancer Presented (3/11/2010)
Researchers affiliated with the IMPACT trial have reported that additional follow-up and more analyses demonstrate a clear survival advantage of Provenge® (sipuleucel-T) versus placebo in men with hormone-refractory prostate cancer. The details of this study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco between March 5 and 7.

Urinary Prostate Cancer Test, PCA3, Predictive of Biopsy Outcomes (3/9/2010)
Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial have reported that the urinary PCA3 test can predict biopsy outcome in men taking dutasteride. The details of two studies were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium held in San Francisco, March 5-7.

Gene Signature Test May Help Predict Recurrences of Prostate Cancer After Prostatectomy (3/8/2010)
Researchers from the University of Texas at San Antonio, the University of Utah, and Myriad Genetics, Inc. have reported that a gene signature test performed on prostate cancer tissue can help predict the probability of recurrent disease in men with localized prostate cancer treated with radical prostatectomy. The details of this study were presented at the 2010 meeting of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.

Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere® (3/5/2010)
Researchers involved in the multicenter international Phase III trial (TROPIC) have reported that cabazitaxel (XRP-6258) was superior to Novantrone® (mitoxantrone) for the treatment of patients with hormone refractory prostate cancer (HRPC) who had failed treatment with Taxotere® (docetaxel). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.